MCID: NSP003
MIFTS: 34

Nasopharyngeal Disease

Categories: Respiratory diseases

Aliases & Classifications for Nasopharyngeal Disease

MalaCards integrated aliases for Nasopharyngeal Disease:

Name: Nasopharyngeal Disease 12 15
Nasopharyngeal Diseases 54 44 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9561
MeSH 44 D009302
NCIt 50 C35723
SNOMED-CT 67 123952009
UMLS 71 C0027438

Summaries for Nasopharyngeal Disease

MalaCards based summary : Nasopharyngeal Disease, also known as nasopharyngeal diseases, is related to lymphoma, non-hodgkin, familial and nasopharyngeal carcinoma. An important gene associated with Nasopharyngeal Disease is PSMB9 (Proteasome 20S Subunit Beta 9), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Lidocaine and Oxymetazoline have been mentioned in the context of this disorder. Affiliated tissues include tonsil and temporal lobe.

Related Diseases for Nasopharyngeal Disease

Diseases related to Nasopharyngeal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 167)
# Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin, familial 30.1 MIR9-1 MIR324 MIR31 MIR30E MIR30A MIR29B1
2 nasopharyngeal carcinoma 29.8 PSMB9 MIR93 MIR9-1 MIR744 MIR34C MIR324
3 nasopharyngitis 11.0
4 epithelioid cell melanoma 10.5 MIR93 MIR9-1
5 leiomyoma, uterine 10.5 MIR30A MIR29C MIR27A MIR21
6 trichorhinophalangeal syndrome, type i 10.5 MIR9-1 MIR30A MIR10B
7 endometriosis of ovary 10.5 MIR9-1 MIR30E MIR141
8 ovarian cystadenocarcinoma 10.5 MIR744 MIR30A MIR17
9 retinal vascular disease 10.5 MIR30A MIR21 MIR199A1 MIR17
10 intestinal benign neoplasm 10.5 MIR21 MIR199A1 MIR17 MIR142
11 ovary adenocarcinoma 10.5 MIR744 MIR30A MIR17
12 endocrine organ benign neoplasm 10.5 MIR93 MIR21 MIR199A1 MIR142
13 extrinsic cardiomyopathy 10.5 MIR21 MIR199A1 MIR142
14 serous cystadenocarcinoma 10.5 MIR30A MIR199A1 MIR10B
15 cervix small cell carcinoma 10.5 MIR199A1 MIR10B
16 heart valve disease 10.5 MIR29B1 MIR21 MIR199A1 MIR17
17 muscle cancer 10.5 MIR9-1 MIR199A1 MIR142
18 aortic valve disease 2 10.5 MIR29B1 MIR21 MIR199A1 MIR17
19 uveal disease 10.5 MIR9-1 MIR199A1 MIR142 MIR125A
20 primary bacterial infectious disease 10.5 MIR93 MIR21 MIR142 MIR125A
21 lower lip cancer 10.5 MIR31 MIR21
22 aortic disease 10.4 MIR29B1 MIR21 MIR199A1 MIR17
23 ovarian serous cystadenocarcinoma 10.4 MIR744 MIR30A MIR17
24 muscular disease 10.4 MIR9-1 MIR21 MIR199A1 MIR142
25 gastrointestinal system benign neoplasm 10.4 MIR30A MIR21 MIR199A1 MIR17 MIR142
26 autoimmune disease of central nervous system 10.4 MIR9-1 MIR27A MIR142 MIR125A
27 bone resorption disease 10.4 MIR93 MIR199A1 MIR142
28 autoimmune disease of the nervous system 10.4 MIR9-1 MIR27A MIR142 MIR125A
29 rectum cancer 10.4 MIR31 MIR21 MIR17 MIR125A
30 bone remodeling disease 10.4 MIR93 MIR199A1 MIR142
31 bronchial disease 10.4 MIR21 MIR17 MIR142
32 chromosomal deletion syndrome 10.4 MIR9-1 MIR31 MIR185 MIR17 MIR142
33 melanoma, uveal 10.4 MIR93 MIR9-1 MIR29C MIR199A1 MIR125A
34 intrinsic cardiomyopathy 10.4 MIR21 MIR199A1 MIR142
35 pancreatitis, hereditary 10.4 MIR199A1 MIR125A MIR10B
36 thyroid gland disease 10.4 MIR9-1 MIR199A1 MIR17 MIR142 MIR125A
37 pleural disease 10.4 MIR30E MIR29C MIR199A1 MIR17 MIR125A
38 retinal cancer 10.4 MIR9-1 MIR199A1 MIR17 MIR142 MIR125A
39 bile duct cancer 10.4 MIR9-1 MIR31 MIR21 MIR199A1 MIR17
40 pleural cancer 10.4 MIR93 MIR30E MIR29C MIR185 MIR17 MIR142
41 diffuse large b-cell lymphoma 10.4 MIR27A MIR21 MIR199A1 MIR17 MIR142
42 tongue disease 10.4 MIR31 MIR30A MIR21 MIR199A1 MIR185 MIR17
43 pulmonary disease, chronic obstructive 10.4 MIR21 MIR199A1 MIR17 MIR142
44 bone sarcoma 10.4 MIR9-1 MIR27A MIR21 MIR199A1 MIR17 MIR142
45 inherited metabolic disorder 10.4 MIR9-1 MIR30A MIR21 MIR199A1 MIR17 MIR142
46 lipid storage disease 10.4 MIR21 MIR199A1 MIR142
47 infratentorial cancer 10.4 MIR9-1 MIR34C MIR324 MIR199A1 MIR17 MIR142
48 digeorge syndrome 10.4 MIR9-1 MIR31 MIR185 MIR17 MIR142
49 bone inflammation disease 10.4 MIR30A MIR21 MIR199A1 MIR17 MIR142 MIR125A
50 lung cancer susceptibility 3 10.4 MIR9-1 MIR31 MIR30A MIR21 MIR17

Graphical network of the top 20 diseases related to Nasopharyngeal Disease:



Diseases related to Nasopharyngeal Disease

Symptoms & Phenotypes for Nasopharyngeal Disease

Drugs & Therapeutics for Nasopharyngeal Disease

Drugs for Nasopharyngeal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
3
Ephedrine Approved Phase 4 299-42-3 9294
4
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
5
Pseudoephedrine Approved Phase 4 90-82-4 7028
6 Respiratory System Agents Phase 4
7 Anesthetics Phase 4
8 Sodium Channel Blockers Phase 4
9 Nasal Decongestants Phase 4
10 Diuretics, Potassium Sparing Phase 4
11 Anesthetics, Local Phase 4
12 Vasoconstrictor Agents Phase 4
13 Pharmaceutical Solutions Phase 4
14 Anti-Arrhythmia Agents Phase 4
15
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
16
Gemcitabine Approved Phase 3 95058-81-4 60750
17
Fluorouracil Approved Phase 3 51-21-8 3385
18
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
19 Immunologic Factors Phase 3
20 Antineoplastic Agents, Immunological Phase 3
21 Immunosuppressive Agents Phase 3
22 Anti-Infective Agents Phase 3
23 Antimetabolites Phase 3
24 Antiviral Agents Phase 3
25 Heptavalent Pneumococcal Conjugate Vaccine
26 Vaccines

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Hypertonic Saline Enhances The Field of View of Clinicians and Ease of Procedures: A Double Blind, Randomized, Controlled Trial Comparing the Efficacy of Intranasal Hypertonic Saline, Xylometazoline, Lidocaine, and Isotonic Saline Completed NCT04214938 Phase 4
2 A Randomized Phase III Non-inferiority Study of Radiotherapy Plus Concurrent Nimotuzumab Versus Cisplatin in Stage II-III Nasopharyngeal Carcinoma Recruiting NCT03837808 Phase 3 Nimotuzumab;Cisplatin
3 GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma:a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial Recruiting NCT03840421 Phase 3 gemcitabine and cisplatin;cisplatin and fluorouracil;cisplatin
4 A Single Center 、Single Arm Phase I/II Clinical Trial of Intensity-modulated Radiotherapy Combined With Toripalimab in the Treating of Unresectable Locally Recurrent Nasopharyngeal Carcinoma. Recruiting NCT03854838 Phase 1, Phase 2 Tolipalimab
5 Effectiveness of PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae in 2 to 5 Years Old Healthy Chinese Children. Completed NCT02133469

Search NIH Clinical Center for Nasopharyngeal Disease

Cochrane evidence based reviews: nasopharyngeal diseases

Genetic Tests for Nasopharyngeal Disease

Anatomical Context for Nasopharyngeal Disease

MalaCards organs/tissues related to Nasopharyngeal Disease:

40
Tonsil, Temporal Lobe

Publications for Nasopharyngeal Disease

Articles related to Nasopharyngeal Disease:

(show top 50) (show all 53)
# Title Authors PMID Year
1
microRNA-18a from M2 Macrophages Inhibits TGFBR3 to Promote Nasopharyngeal Carcinoma Progression and Tumor Growth via TGF-β Signaling Pathway. 61
33006671 2020
2
Is otitis media with effusion associated with Samter's triad a new nosological entity? A preliminary report on inflammatory mediator production. 61
32785783 2020
3
Rehabilitation in an Italian thermal setting: a new therapeutic strategy for patients with musculoskeletal disability-the results of an Italian survey. 61
31342242 2020
4
Chordoma with lung metastases at initial presentation of a pediatric patient. 61
32055265 2020
5
Intestinal Flora Disruption and Novel Biomarkers Associated With Nasopharyngeal Carcinoma. 61
31867274 2019
6
TCR repertoire profiling of tumors, adjacent normal tissues, and peripheral blood predicts survival in nasopharyngeal carcinoma. 61
30155576 2018
7
Challenges of modern medicine - geriatric otolaryngology or the advantages of cooperation between an otolaryngologist and a geriatrician. 61
30920384 2018
8
Nasopharyngeal carcinoma presenting as an inconspicuous primary lesion with extensive cavernous sinus involvement and temporal lobe extension: a case report and review of literature. 61
29026572 2017
9
Paediatric nasopharyngeal cytology: a new diagnostic opportunity? 61
27039342 2016
10
Preliminary study of differentiating smears from cancerous and non-cancerous nasopharyngeal tissue using confocal Raman spectroscopy. 61
26612357 2016
11
Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma. 61
27062704 2016
12
Expression of GRIN2A in benign and malignant nasopharyngeal diseases and its clinical significance. 61
26681223 2015
13
Expression and clinical significance of LRRC4 in benign and malignant nasopharyngeal diseases. 61
26662436 2015
14
[Primary nasopharyngeal tuberculosis presenting as durative aural fullness: one case report and literature review]. 61
25219213 2014
15
Eight years of clinical findings and biopsy results of nasopharyngeal pathologies in 1647 adult patients: a retrospective study. 61
25654951 2014
16
Nasopharyngeal disease in cats: 1. Diagnostic investigation. 61
22511473 2012
17
Nasopharyngeal disease in cats: 2. Specific conditions and their management. 61
22511474 2012
18
Nasopharyngeal trichobezoar foreign body in a cat. 61
20974406 2010
19
Clinical findings, rhinoscopy and histological evaluation of 54 dogs with chronic nasal disease. 61
20706033 2010
20
[Clinical applications of magnifying laryngoscopy on nasopharyngeal examination.]. 61
20193617 2009
21
[Imaging of nasopharyngeal diseases]. 61
19639275 2009
22
[Imaging of nasopharyngeal diseases]. 61
19023557 2009
23
Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. 54
17471168 2007
24
Computed tomographic evidence of bulla effusion in cats with sinonasal disease: 2001-2004. 61
17063699 2006
25
Distribution of leucocyte subsets in the canine pharyngeal tonsil. 61
16959260 2006
26
[Diagnostic value of combined detection of CYFRA21-1 and TSGF in nasopharyngeal carcinoma]. 61
15934283 2005
27
[Otalgia as presentation of primary nasopharynx tuberculosis]. 61
16475546 2005
28
[Value of CT scan in the early diagnosis of nasopharyngeal tumor]. 61
15318638 2004
29
Capnocytophaga sp. isolated from a cat with chronic sinusitis and rhinitis. 61
14605195 2003
30
Feline inflammatory polyps: historical, clinical, and PCR findings for feline calici virus and feline herpes virus-1 in 28 cases. 61
12468312 2002
31
Vision-threatening complications of nasal T/NK lymphoma. 61
12208253 2002
32
Balloon dilation for the treatment of chronic recurrent nasopharyngeal stenosis in a cat. 61
11873954 2002
33
[The thin sectional anatomy and MRI of the eustachian tube]. 61
11944475 2002
34
Lymphadenitis, trans-epidermal elimination and unusual histopathology in human rhinosporidiosis. 61
12000127 2002
35
Nasopharyngeal diseases in cats: a retrospective study of 53 cases (1991-1998). 61
10580903 1999
36
Temporal bone tumours in patients irradiated for nasopharyngeal neoplasm. 61
10435128 1999
37
[The role of acoustic rhinometry in the evaluation of the volume of nasopharynx before and after adenoidectomy]. 61
11717890 1998
38
Nasopharyngeal cryptococcosis. 61
9258419 1997
39
[The cephalometric characteristics of the facial skeleton and base of the skull in prognathic bite]. 61
8236306 1993
40
[Effect of chronic nasopharyngeal diseases among 14-year-old students and extra-curricular factors on school performance]. 61
1788518 1991
41
MRI of the nasopharynx. 61
2645605 1989
42
Patterns of failure in nasopharyngeal cancer treated with megavoltage irradiation. 61
3088681 1986
43
Secondary lymphoma of Waldeyer's ring: natural history and association with prior extranodal disease. 61
3953968 1986
44
Hodgkin's disease in the Waldeyer's ring. 61
7361330 1980
45
The influence of nasal respiration on the function of the auditory tube. 61
84719 1978
46
[PAIN IN NASOPHARYNGEAL DISEASES]. 61
14095856 1963
47
[Relations of nasopharyngeal diseases to non-specific lung diseases]. 61
14027833 1963
48
[Treatment & prevention of acute nasopharyngeal diseases in a communal environment; a new oral bismuth derivative]. 61
13446630 1957
49
Management of some benign nasopharyngeal diseases in the adult; supplementary report. 61
13356856 1956
50
[A new aerosol in nasopharyngeal diseases: preliminary report]. 61
13168537 1954

Variations for Nasopharyngeal Disease

Expression for Nasopharyngeal Disease

Search GEO for disease gene expression data for Nasopharyngeal Disease.

Pathways for Nasopharyngeal Disease

Pathways related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 MIR9-1 MIR34C MIR324 MIR31 MIR30E MIR30A
2 11.53 MIR9-1 MIR34C MIR29B1 MIR21 MIR125A
3 11.38 MIR34C MIR30E MIR30A MIR17
4 11.2 MIR93 MIR34C MIR27A
5 10.88 MIR34C MIR29C MIR29B1

GO Terms for Nasopharyngeal Disease

Cellular components related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 MIR93 MIR744 MIR31 MIR30E MIR30A MIR29C
2 extracellular exosome GO:0070062 9.81 PSMB9 MIR9-1 MIR29C MIR29B1 MIR27A MIR21
3 extracellular vesicle GO:1903561 9.32 MIR125A MIR17 MIR185 MIR21 MIR27A MIR29B1

Biological processes related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.02 MIR21 MIR29B1 MIR29C MIR9-1 MIR93
2 positive regulation of angiogenesis GO:0045766 9.86 MIR199A1 MIR21 MIR30A MIR31
3 negative regulation of cell migration GO:0030336 9.85 MIR21 MIR29B1 MIR29C MIR9-1 MIR93
4 negative regulation of inflammatory response GO:0050728 9.83 MIR141 MIR142 MIR31
5 negative regulation of angiogenesis GO:0016525 9.81 MIR125A MIR185 MIR21 MIR29C
6 negative regulation of protein kinase B signaling GO:0051898 9.78 MIR29B1 MIR29C MIR34C
7 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.77 MIR21 MIR29B1 MIR29C
8 negative regulation of gene expression GO:0010629 9.76 MIR125A MIR17 MIR185 MIR21 MIR27A MIR29B1
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.75 MIR17 MIR21 MIR27A
10 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.72 MIR199A1 MIR21 MIR30E
11 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.71 MIR10B MIR27A MIR31
12 negative regulation of sprouting angiogenesis GO:1903671 9.7 MIR17 MIR30E MIR34C
13 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.67 MIR10B MIR21 MIR27A
14 negative regulation of protein secretion GO:0050709 9.65 MIR29B1 MIR93
15 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.65 MIR17 MIR31
16 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.65 MIR125A MIR21 MIR29B1
17 regulation of DNA methylation GO:0044030 9.64 MIR29B1 MIR29C
18 positive regulation of connective tissue replacement GO:1905205 9.64 MIR199A1 MIR34C
19 negative regulation of matrix metallopeptidase secretion GO:1904465 9.63 MIR199A1 MIR29B1
20 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.63 MIR185 MIR27A
21 positive regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902110 9.62 MIR29B1 MIR29C
22 negative regulation of vascular endothelial growth factor production GO:1904046 9.62 MIR125A MIR17 MIR199A1 MIR93
23 negative regulation of metallopeptidase activity GO:1905049 9.61 MIR199A1 MIR29B1
24 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.61 MIR17 MIR199A1 MIR34C
25 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.59 MIR17 MIR21
26 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.58 MIR21 MIR27A
27 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR17 MIR21 MIR29B1
28 gene silencing by miRNA GO:0035195 9.58 MIR27A MIR21 MIR199A1 MIR185 MIR17 MIR142
29 negative regulation of circulating fibrinogen levels GO:0061754 9.57 MIR29B1 MIR29C
30 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.56 MIR17 MIR185 MIR199A1 MIR27A
31 miRNA mediated inhibition of translation GO:0035278 9.56 MIR10B MIR17 MIR21 MIR27A MIR29B1 MIR29C
32 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.54 MIR125A MIR141 MIR31

Molecular functions related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.77 MIR10B MIR125A MIR141 MIR142 MIR17 MIR21
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.53 MIR10B MIR125A MIR141 MIR142 MIR17 MIR185

Sources for Nasopharyngeal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....